发明名称 |
Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments |
摘要 |
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
|
申请公布号 |
US2006147959(A1) |
申请公布日期 |
2006.07.06 |
申请号 |
US20050294621 |
申请日期 |
2005.12.05 |
申请人 |
DANA-FARBER CANCER INSTITUTE, INC. |
发明人 |
BELL DAPHNE W.;HABER DANIEL A.;JANNE PASI A.;JOHNSON BRUCE E.;LYNCH THOMAS J.;MEYERSON MATTHEW;PAEZ JUAN G.;SELLERS WILLIAM R.;SETTLEMAN JEFFREY E.;SORDELLA RAFFAELLA |
分类号 |
C12Q1/68;C12Q1/48;G01N33/574;G01N33/74 |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|